GIP/GLP-1 dual agonist research

Tirzepatide.
1 vendor · ¥3255–3255

Dual GIP/GLP-1 receptor agonist, FDA- and EMA-approved as Mounjaro and Zepbound. Research-vial tirzepatide is a different, unapproved product, not made or reviewed as those medicines, and not for human use.

Approved-analogue classLyophilised vialAlso known as:Mounjaro · Zepbound

See all 1 listings ↓Compare all

Compound specification

Formula

C₂₂₅H₃₄₈N₄₈O₆₈

CAS

2023788-19-2

4813 g/mol

Half-life

Approximately 5 days (human; Mounjaro prescribing information, section 12.3)

Storage

Lyophilised powder below −15 °C in a tightly closed container, shielded from light; equilibrate the sealed vial to room temperature before opening. Reconstituted vials 2–8 °C.

Sizes

10 mg, 15 mg

What it is

The compound. Origin, research and regulatory reality.

Tirzepatide is a synthetic dual GIP/GLP-1 receptor agonist developed by Eli Lilly: a 39-amino-acid peptide engineered from the native GIP sequence with a fatty-diacid moiety for albumin binding. The FDA approved it as Mounjaro for type 2 diabetes on 13 May 2022 and as Zepbound for chronic weight management on 8 November 2023; Mounjaro is also authorised by the EMA.

The SURPASS trial programme characterised its dual-receptor mechanism and glucose-lowering action in adults with type 2 diabetes, including SURPASS-1 (Rosenstock et al., 2021) and a head-to-head comparison with semaglutide (Frías et al., 2021). The SURMOUNT programme (Jastreboff et al., 2022) studied its effect on body weight in adults with obesity or overweight through the same mechanism.

As Mounjaro and Zepbound, tirzepatide is prescription-only, manufactured and reviewed under FDA and EMA oversight, and its US prescribing information carries a boxed warning for thyroid C-cell tumours observed in rats. Research-use-only tirzepatide vials sold outside that supply chain are not those products and have not been reviewed for safety, effectiveness or quality. The FDA has warned of fraudulently compounded tirzepatide and has warned companies that illegally sold unapproved tirzepatide falsely labelled ‘for research purposes’.

Live vendor register · sorted by price

Every vendor. Same compound, sorted ascending.

TIRZEPATIDE · price-normalised

1 listing · unflagged vendors first

Flagged vendors · documented, never recommended

QSC PeptidesVID-QSC-PEPT · Kit of 10 · from $210

15 mg

99%

HPLC · MS · Janoshik

In stock

7–14 days (international)

¥3,255

Why →

Representative literature

Research context. Recent peer-reviewed work.

2021 · Lancet

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)

DOI ↗

2021 · N. Engl. J. Med.

Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)

cited by n = 1879DOI ↗

2022 · N. Engl. J. Med.

Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)

cited by n = 2539DOI ↗

Common questions

Frequently asked.

Is tirzepatide legal to buy?

Mounjaro and Zepbound are prescription-only medicines. Research-use-only tirzepatide vials are sold for laboratory research, not human use; RUO labelling does not make personal use or import legal everywhere.

How does research-vial tirzepatide differ from Mounjaro or Zepbound?

The approved pens are manufactured and reviewed under FDA/EMA oversight and carry a boxed thyroid-tumour warning based on reviewed safety data. Research vials come from an unreviewed supply chain with no verified purity or delivery controls.

What should a CoA show for tirzepatide?

HPLC purity, LC-MS mass confirmation matching C225H348N48O68 (MW ~4813), a lot number, an independent third-party lab name and a test date. The FDA has warned of fraudulently labelled compounded tirzepatide products.

Same research area